Marina Frimer

Dr. Marina Frimer


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2003 in Archives of Environmental Health: An International Journal
Verified
Journal Article
Closed access
JMJoseph J. Mangano
Joseph J. Mangano
JSJanette Sherman
Janette Sherman
CCCarolyn Chang
Carolyn Chang
ADAmie Dave
Amie Dave
EFElyssa Feinberg
Elyssa Feinberg
MFMarina Frimer
Marina Frimer
Numerous reports document elevated cancer rates among children living near nuclear facilities in various nations. Little research has examined U.S. rates near the nation's 103 operating reactors. This study determined that cancer incidence for children < 10 yr of age who live within 30 mi (48 km) of each of 14 nuclear plants in the eastern United States (49 counties with a population > 16.8 million) exceeds the national average. The excess 12.4% risk suggests that 1 in 9 cancers among children who reside near nuclear reactors is linked to radioactive emissions. If cancer incidence in 5 western states is used as a baseline, the ratio is closer to 1 in 5. Incidence is particularly elevated for leukemia. Childhood cancer mortality exceeds the national average in 7 of the 14 study areas.

1 October 2019 in Gynecologic Oncology
Verified
Journal Article
Closed access
KMKoji Matsuo
Koji Matsuo
JCJames C. Cripe
James C. Cripe
KKKatherine C Kurnit
Katherine C Kurnit
MKMichiko Kaneda
Michiko Kaneda
AGAudrey S. Garneau
Audrey S. Garneau
LRLynda D. Roman
Lynda D. Roman

1 November 2016 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
EMEirwen M. Miller
Eirwen M. Miller
YSYing Sun
Ying Sun
IRIngride Richardson
Ingride Richardson
MFMarina Frimer
Marina Frimer
Endometriosis is associated with increased rates of ovarian, particularly clear cell, adenocarcinomas. Malignant transformation of ovarian endometriosis is most common but rare cases have been reported in the bladder, abdominal wall, diaphragm, and rectum. We present the case of a 44-year-old female with vesical clear cell adenocarcinoma arising in a background of endometriosis in the absence of other pelvic endometriosis. The malignancy was diagnosed on transurethral resection of bladder tumor and managed with radical surgery. Histology and immunohistochemical findings were consistent mullerian origin and indistinguishable from similar tumors arising in the female genital tract. Extrapolating from the gynecologic literature, the recommendation was made for adjuvant chemotherapy. Further studies are needed to clarify the optimal treatment paradigm for ovarian and bladder clear cell adenocarcinomas.

1 April 2016 in Gynecologic Oncology
Verified
Journal Article
Closed access
MFMarina Frimer
Marina Frimer
KLKelly S Levano
Kelly S Levano
ARAlicia Rodriguez-Gabin
Alicia Rodriguez-Gabin
YWYanhua Wang
Yanhua Wang
GGGary L. Goldberg
Gary L. Goldberg
JHJune Y. Hou
June Y. Hou

1 July 2015 in Gynecologic Oncology
Verified
Journal Article
Closed access
MFMarina Frimer
Marina Frimer
CSChang Sun
Chang Sun
TMThomas McAndrew
Thomas McAndrew
BSBenjamin Smith
Benjamin Smith
AHAriana Harari
Ariana Harari
RBRobert D. Burk
Robert D. Burk

1 November 2019 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
MFMarina Frimer
Marina Frimer
LTL.B. Turker
L.B. Turker
VSV. Shankar
V. Shankar
RCR. Cardaci
R. Cardaci
AAA.R. Van Arsdale
A.R. Van Arsdale
NNN. Nevadunsky
N. Nevadunsky
Gynecologic cancer survivors report sexual health among their highest concerns. The aim of this study was to identify the prevalence of sexual dysfunction (SD) in survivors of gynecologic malignancies and to evaluate the association of sexual function with race, ethnicity and treatment modality. In this study, survivors of endometrial, cervical, vaginal, and vulvar cancer who presented to the gynecologic oncology practice were asked to self-administer the Female Sexual Function Index (FSFI) survey to evaluate their sexual function. The prevalence of SD was estimated and its association with demographic and clinical co-variates was analyzed. Of the 155 participants, the prevalence of SD was 44.5% (95%CI: 36.7-52.7). Patients were significantly more likely to report SD if they did not currently have a partner (69% vs 22% p < .01). Abstinence within six months of their cancer diagnosis was also associated with SD (72% vs 26% p < .01). Patients who self-identified as black race compared to white race were three times more likely to have SD (OR = 3.9, 95% CI 1.1-14.3). Patients who received adjuvant chemotherapy and radiation therapy compared to those who did not among the entire cohort had an increased risk of SD (OR = 3.4, 95% CI 1.2-9.6). In our diverse population, almost half of our patients were identified to have SD. Black as compared to white race reported significantly higher sexual dysfunction. An increased risk for sexual dysfunction was observed among those women who received chemotherapy and radiation with or without surgery. Survivorship is an important issue for women with gynecologic malignancies. This study addresses the high rates of sexual dysfunction in a racially diverse patient population.